Healios KK (TSE:4593) Stock Based Compensation: 円0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4593 Healios KK TSE:4593
50 GF Score
Price 円239.00
GF Value 円56.47
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Stock Based Compensation?

Healios KK TSE:4593 -5.91% 50 Stock Based Compensation is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:4593 with a GF Score™ of 50/100 and a GF Value™ of 円56.47 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Healios KK's Stock Based Compensation for the three months ended in Mar. 2026 was 円0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was 円0.00 Mil.

Healios KK Stock Based Compensation Related Terms

Healios KK Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Healios KK's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK Stock Based Compensation Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4593
50GF Score
Healios KK TSE:4593
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

What does a Stock Based Compensation of 円0.00 Mil mean?
Healios KK (TSE:4593) has a Stock Based Compensation of 円0.00 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Healios KK and its competitors.
Is Healios KK's Stock Based Compensation too high?
Healios KK's current Stock Based Compensation is 円0.00 Mil. Overall, Healios KK has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Stock Based Compensation compare to VRTX and REGN?
Healios KK's Stock Based Compensation of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Healios KK and its competitors. Healios KK's current Stock Based Compensation is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (TSE:4593) is currently considered Significantly Overvalued. The stock's GF Value™ is 円56.47, compared to a current price of 円239.00 — trading 323.2% above its estimated fair value. The current Stock Based Compensation is 円0.00 Mil. Healios KK's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Healios KK (TSE:4593), the current Stock Based Compensation is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (TSE:4593) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of 円239.00 is trading 323.2% above its estimated GF Value™ of 円56.47. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for TSE:4593:

  • Stock Based Compensation: 円0.00 Mil
  • GF Value™: 円56.47 vs. price of 円239.00 (323.2% above fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the TSE:4593 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healios KK Business Description

Other Exchanges HLOSF:USA6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
50GF Score

Get the complete analysis for TSE:4593

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円239.00
Price
円56.47
GF Value